Karyopharm Therapeutics | KPTI - Beneficio Bruto En Ventas

Precio De Mercado
8.00
Cambio Diario
-0.16 -1.96%
Mensual
-8.57%
Anual
86.48%
Q2 Expectativa
7.78




Beneficio Bruto En Ventas Cambio Fecha
AbbVie USD 10.47B 605M 2025-09
Abbott USD 6.54B 625M 2025-12
Amgen USD 6.48B 307M 2025-09
AstraZeneca USD 12.39B 5M 2025-12
BioCryst Pharmaceuticals USD 153.05M 4.16M 2025-12
Bristol-Myers Squibb USD 8.79B 110M 2025-09
Eli Lilly USD 14.59B 1.48B 2025-09
Enanta Pharmaceuticals -22.29M 23.75M 2024-12
GlaxoSmithKline GBP 6.18B 106M 2025-12
Incyte USD 1.39B 118.68M 2025-12
J&J USD 16.6B 118M 2025-12
Karyopharm Therapeutics USD 32.6M 63.38M 2025-12
MacroGenics USD 31.11M 30.14M 2025-12
Merck USD 13.42B 431M 2025-09
Nektar Therapeutics USD 21.81M 8.06M 2025-12
Novartis USD 10.25B 570M 2025-12
Novartis USD 10.82B 694M 2025-09
Pfizer USD 3.54B 7.61B 2025-09
Regeneron Pharmaceuticals USD 3.3B 67M 2025-12
Roche Holding CHF 22.09B 10.04B 2025-12
Sangamo BioSciences -2.39M 1.09M 2024-06
Takeda JPY 790.55B 262.97B 2025-12
Tectonic Therapeutic USD 0 0 2025-03
TG Therapeutics USD 154.43M 20.81M 2025-12
Ultragenyx Pharmaceutical USD 178M 46.06M 2025-12
Xencor USD 21M 22.61M 2025-09